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Mutations causing aberrant splicing are frequently implicated in human diseases including
cancer. Here, we establish a high-throughput screen of randomly mutated minigenes to
decode the cis-regulatory landscape that determines alternative splicing of exon 11 in the
proto-oncogene MST1R (RON). Mathematical modelling of splicing kinetics enables us to
identify more than 1000 mutations affecting RON exon 11 skipping, which corresponds to the
pathological isoform RONΔ165. Importantly, the effects correlate with RON alternative spli-
cing in cancer patients bearing the same mutations. Moreover, we highlight heterogeneous
nuclear ribonucleoprotein H (HNRNPH) as a key regulator of RON splicing in healthy tissues
and cancer. Using iCLIP and synergy analysis, we pinpoint the functionally most relevant
HNRNPH binding sites and demonstrate how cooperative HNRNPH binding facilitates a
splicing switch of RON exon 11. Our results thereby offer insights into splicing regulation and
the impact of mutations on alternative splicing in cancer.
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A lternative splicing constitutes a major step in eukaryoticgene expression. More than 90% of human genes undergoalternative splicing1,2, which allows the production of
distinct protein isoforms with different functionalities3,4 and
plays a critical role in development and tissue identity5. Strik-
ingly, tumour suppressor genes and proto-oncogenes are parti-
cularly susceptible to splicing defects. Moreover, abnormally
expressed splicing factors can have oncogenic properties6, and
changes in alternative splicing contribute to key processes in
cancer initiation and progression7–9. A detailed characterisation
of splicing mechanisms is therefore fundamental to our under-
standing of human biology and disease.
Splicing is an important step in the maturation of nascent
transcripts that comprises excision of introns and joining of
exons. During alternative splicing, certain exons can be either
included or excluded, thus leading to different transcript iso-
forms. Splicing is catalysed by the spliceosome, a multi-subunit
complex that recognises the 5′ and 3′ splice sites and ﬂanking
sequence elements in the pre-mRNA. The latter include the
polypyrimidine tract (Py-tract) and the branch point upstream of
each exon10. In addition to these core splice signals, multiple cis-
regulatory elements reside in exons and ﬂanking introns which
can be primary RNA sequence elements as well as RNA sec-
ondary structures. The recognition of cis-regulatory elements by
trans-acting RNA-binding proteins (RBPs) guides the spliceo-
some and ultimately determines the splicing decision at each
alternative exon. Altogether, the information in the pre-mRNA
sequence and how it is interpreted by RBPs is commonly referred
to as the splicing code11–13.
Despite many efforts to understand the molecular rules of
splicing, our knowledge about cis-regulatory elements and trans-
acting factors in most cases remains far from complete. Recent
bioinformatic studies aimed to decipher the splicing code by
predicting the impact of sequence variants on alternative splicing
decisions14,15. Moreover, mutagenesis screens were employed to
map sequence determinants of alternative splicing. However,
these studies were limited to targeted mutagenesis of synthetic
reporter constructs or short exonic regions16–18.
Recepteur d’origine nantais (RON) is a receptor tyrosine kinase
encoded by the proto-oncogeneMST1R (also referred to as RON).
Under normal conditions, the protein is cleaved to form a
functional receptor. Skipping of RON alternative exon 11 results
in the isoform RONΔ165, which remains as a single-chain pro-
tein. Spontaneous oligomerisation of RONΔ165 results in con-
stitutive phosphorylation19 that promotes epithelial-to-
mesenchymal transition and contributes to tumour invasive-
ness20–23. Consistently, RONΔ165 is frequently upregulated in
solid tumours, including ovarian, pancreatic, breast and colon
cancers21,24,25. On the molecular level, previous studies identiﬁed
a handful of mutations that inﬂuence RON exon 11 splicing26,27.
Moreover, several RBPs were reported to regulate RON spli-
cing7,26,27. For instance, heterogeneous nuclear ribonucleoprotein
H (HNRNPH; collectively referring to HNRNPH1 and its close
paralogue HNRNPH2 which are 96% identical at the amino acid
level28) was found to repress RON exon 11 inclusion via binding
within the alternative exon. While these studies suggested that
RON splicing is heavily regulated, most cis-regulatory elements
remain unknown.
Here, we establish a high-throughput mutagenesis approach to
comprehensively characterise the regulatory landscape of RON
exon 11 splicing. Starting from a library of almost 5800 randomly
mutated minigenes, we employ a mathematical model of the
splicing kinetics to detect more than 1000 point mutations that
signiﬁcantly affect RON alternative splicing. Importantly, the
deduced single mutation effects correlate with the splicing levels
in cancer patients bearing the same mutations. Moreover, we
comprehensively characterise how HNRNPH acts as a key reg-
ulator of healthy and pathophysiological RON splicing by
recognising multiple cis-regulatory elements in a cooperative
fashion. Our mutagenesis screening approach promises insights
into the splicing effects of mutations in humans and the
mechanisms of alternative splicing regulation in general.
Results
Random mutagenesis introduces 18,000 mutations. To sys-
tematically study the cis-regulatory sequence elements that con-
trol RON alternative splicing, we designed an in vivo screening
approach based on random mutagenesis of a splicing reporter
minigene (Fig. 1a). The minigene harbours RON exon 11 together
with the complete ﬂanking introns and the constitutive exons 10
and 12 (Supplementary Fig. 1a). We conﬁrmed that the minigene
gives rise to the same transcript isoforms as the endogenous gene
in human HEK293T cells (Supplementary Fig. 1b). Moreover,
mutations in a known cis-regulatory element led to increased
RON exon 11 skipping as reported previously7 (Supplementary
Fig. 1c). We next ampliﬁed the minigene with error-prone PCR to
spread mutations randomly across all exons and introns. A 15-nt
barcode sequence was introduced downstream of constitutive
exon 12 via a randomised sequence in the reverse primer to
uniquely identify each mutated minigene variant. Upon vector
ligation and ampliﬁcation, we pooled ~6000 clones into a mini-
gene library (Supplementary Fig. 1d). As an internal reference,
the library was supplemented with wild-type (wt) minigene var-
iants that carry distinct barcode sequences but no mutations.
To map the introduced mutations, we sequenced the minigene
library with 300-nt paired-end reads and ﬁve overlapping
amplicons. The 15-nt barcode included in each read pair enabled
us to assign and reconstruct the complete sequence of all
minigene variants in the library (Supplementary Fig. 2a). Using a
custom-tailored analysis pipeline (Supplementary Fig. 2b), we
capture a total of 5791 unique minigene variants (see Methods),
including 5200 with randomly introduced mutations as well as
591 with the wt sequence (Supplementary Data 1). Mutation
calling identiﬁed 18,948 point mutations with an average
frequency of 3.6 mutations per minigene variant. The mutations
are randomly spread across the RON minigene, such that 97% of
the positions are mutated at least ten times within the library
(average 28 times per position; Supplementary Fig. 2c–e). We
validated the accuracy of mutation calling with Sanger sequencing
of 59 randomly selected minigene variants, conﬁrming all 169
mutations without additional false positives.
Targeted RNA-seq quantiﬁes alternative splicing outcome. To
measure the splicing outcome, we transfected the library as a pool
into human HEK293T cells where the minigenes are transcribed
and spliced. We devised a targeted RNA-seq strategy based on
300-nt paired-end reads, which allows us to assemble the com-
plete sequence of all splice products including the 15-nt barcode
sequence that is present in all read pairs (Supplementary Fig. 2f,
g). A total of 5598 (97%) minigene variants were captured in all
three independent biological RNA-seq replicates (Supplementary
Fig. 2h and Supplementary Data 1). From the RNA-seq data, we
could reconstruct and quantify 163 distinct splice isoforms. The
most abundant isoforms reﬂect the canonical splicing events, i.e.,
alternative exon (AE) inclusion and skipping, as well as partial
and full intron retention (IR) (Fig. 1b, g and Supplementary
Fig. 2g). In addition, we detected non-canonical splicing events at
82 and 71 cryptic 3′ and 5′ splice sites, respectively, which are
collectively referred to as ‘other’ (Fig. 1c). For instance, mutations
disrupting the 3′ splice site of the downstream constitutive exon
12 trigger activation of a cryptic AG (marked by one asterisk in
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05748-7
2 NATURE COMMUNICATIONS |  (2018) 9:3315 | DOI: 10.1038/s41467-018-05748-7 | www.nature.com/naturecommunications
Fig. 1b, g). While the overall abundance of the cryptic isoforms in
the RNA-seq libraries is low, they can dominate the splice pro-
ducts of individual minigene variants (Fig. 1b).
For the wt minigenes, i.e., in the absence of mutations, the
frequency of the AE inclusion isoform (i.e., the ratio of AE
inclusion over the sum of all measured isoforms) shows little
variance, supporting the notion that confounding effects of the
barcode sequences are negligible (Fig. 1d). In contrast, almost half
of the mutated minigenes (2248, 45%) show more than 10%
deviation in AE inclusion, suggesting that many introduced
mutations strongly affect the splicing outcome (Fig. 1d). As
expected, any mutation within the splice sites of RON exon 11
completely abolishes AE inclusion (Fig. 1d, f). We validated the
accuracy of the RNA-seq quantiﬁcation using individual RT-PCR
measurements of the 59 Sanger-sequenced minigene variants
(Fig. 1e and Supplementary Data 8). We conclude that the
random mutagenesis approach enables precise high-throughput
quantiﬁcation of alternative splicing.
Linear regression modelling infers single mutation effects.
Since each mutated minigene variant carries several mutations,
the measured splicing changes are an overlay of multiple effects.
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Consequently, a set of minigenes that share a given mutation
displays a certain degree of variation in their splicing behaviour
(Fig. 1f and Supplementary Data 2). To extract the impact of
individual mutations, we made the simplifying assumption that
mutations affect splicing independently and derived a linear
regression-based mathematical modelling approach. In the linear
regression model, the splicing change of each minigene relative to
wt is described as the sum of single mutation effects (Fig. 2a). By
ﬁtting this model to the measured combined mutation effects, the
underlying single mutation effects can be inferred.
To assess whether additivity of mutation effects can indeed be
assumed, we analysed a reaction network representing splicing of
the RON minigene using kinetic modelling (Supplementary
Note 1 and Supplementary Fig. 3a). Model analysis shows that
only when we consider splice isoform ratios (i.e., ratios of two
measured isoform frequencies), mutation effects do not depend
on the presence of other mutations in a minigene. Thus, for splice
isoform ratios, mutation effects add up in log-space and a linear
regression can be performed. In contrast, at the level of individual
splice isoform frequencies (or related metrics such as percent
spliced-in, PSI), mutation-induced fold changes depend on the
mutational background and are thus not additive in log-space.
We directly conﬁrmed the additive behaviour of isoform ratios
for mutations that are present as single mutation minigenes and
simultaneously occur as combinations in double/triple mutation
minigenes (Supplementary Fig. 4).
To integrate the full mutation information available in the data
set, we formulated ﬁve separate regression models, each
expressing the splicing outcome as a ratio of one splice isoform
relative to the reference AE inclusion isoform. By simultaneously
ﬁtting the complete set of linear equations, each reﬂecting one
minigene, to the experimental data, we were able to estimate
1800 single mutation effects. Based on the regression results, we
could infer the frequency of ﬁve canonical splice isoforms for
each of these single mutations, or combinations thereof
(Supplementary Table 1 and Supplementary Data 3). The models
ﬁt the data with high accuracy, as judged by the excellent
correlation between model ﬁt and experimental data (Pearson
correlation coefﬁcient, r= 0.99, P value < 2e−16; Fig. 2b and
Supplementary Fig. 5a, b). This supports our assumption that
mutations affect splicing independently and can be described as a
sum of single mutation effects (Supplementary Figs. 3b and 4a).
To test for ability of the model to infer novel combined
mutations, we employed tenfold cross-validation, in which the
model was ﬁtted to 90% of the minigenes and used to predict the
splicing outcome for the remaining 10%. The excellent cross-
validation accuracy (Pearson correlation coefﬁcients r=
0.96–0.97, P value < 2e−16; Supplementary Fig. 6) outperformed
alternative regression model variants that were ﬁtted directly to
the measured splice isoform frequencies (Supplementary Note 2
and Supplementary Fig. 7a, b). The inference power of the model
for novel single mutation effects was assessed by separately
leaving out one of >500 single-mutation minigene variants and
ﬁtting the model to the remaining data, or to subsets, in which
further occurrences of the considered mutation were left out. This
procedure revealed that the inference error for a single mutation
effect decays with increasing occurrence of a mutation in our data
set as E  1= ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃoccurrencepð Þ (see Supplementary Note 2, Fig. 2c
and Supplementary Fig. 5c). For mutations with occurrences >5
(i.e., present in more than ﬁve minigene variants), the estimated
standard deviation of the inference error levels around 6%,
suggesting that at sufﬁciently high occurrence the model
inference accuracy is close to the experimental variation for wt
minigene variants (3% standard deviation). We compared the
cross-validation results to a simpler proxy in which single
mutations effects are estimated from the median splice isoform
frequencies over all minigenes containing a particular mutation.
Even though the latter approach should average out the effect of
accompanying mutations when enough minigenes are present,
the regression model outperforms the median-based estimation
across all occurrence levels (Fig. 2c and Supplementary Fig. 5c, d).
To independently validate the modelling results, we generated
26 minigene variants with individual mutations for which the
model predictions substantially differed from the simpler
median-based estimation of single mutations effects. Using RT-
PCR to assess splicing outcomes, we ﬁnd a strong correlation with
the splice isoform frequencies inferred by the model (Fig. 2d,
Supplementary Fig. 4b and Supplementary Data 8). The gain in
accuracy by the model is particular apparent for mutations with a
low frequency, i.e., appearing in only few minigenes. We conclude
that the regression model offers a reliable method to quantify the
impact of single mutations on RON alternative splicing.
Numerous positions contribute to RON alternative splicing.
Using the model inference for HEK293T cells, we ﬁnd a total of
778 mutations that signiﬁcantly alter the frequency of at least one
isoform (henceforth called splicing-effective mutations; >5%
change in isoform frequency, 5% false discovery rate, FDR;
Fig. 2e–g, Supplementary Fig. 8 and Supplementary Table 2). At
the 5′ splice site of RON exon 11, we observe a good correlation
between AE inclusion levels and in-silico-predicted splice-site
Fig. 1 High-throughput mutagenesis screen provides quantitative splicing information across the RON minigene. a High-throughput detection of splicing-
effective mutations. Mutagenic PCR creates mutated minigene library (left) that gives rise to alternatively spliced transcripts (middle). Mutations and
corresponding splicing products are characterised by DNA and RNA sequencing, respectively, and linked by unique 15-nt barcode sequence in each
minigene (coloured boxes). Black and grey boxes depict constitutive and alternative exons, respectively. b Nine most frequent isoforms found in
HEK293T cells. Bar diagram shows total frequency in RNA-seq library (black) and maximal frequency for any individual minigene variant (grey). Asterisks
mark non-canonical isoforms from cryptic 3′ splice site usage upon mutations at positions marked in g. AE, alternative exon, IR, intron retention, other,
non-canonical isoforms. c Occurrence of distinct splice junctions in HEK293T cells. Line thickness and colour represent number of minigene variants
producing a given junction (only junctions accounting for ≥1% of all junctions for a given minigene). d Boxplot showing distribution of AE inclusion
frequencies (as % of all isoforms) for all wild-type (wt) and mutated minigenes and a subset with mutations in splice sites (ss) of RON exon 11. Boxes
represent quartiles, centre lines denote 50th percentile, and whiskers extend to most extreme values within 1.5× interquartile range (IQR). e Validation of
AE inclusion frequencies for 59 randomly selected minigene variants. Scatterplot compares the RNA-seq quantiﬁcation to semiquantitative RT-PCR for
individual minigene variants in HEK293T cells. r, Pearson correlation coefﬁcient and associated P value. f Mutational landscape around the 3′ splice site of
RON exon 11. Boxplot of AE inclusion frequencies in HEK293T cells for all minigenes with mutation at indicated positions (x-axis). Box representation as in
d. Colours illustrate inserted nucleobase (see legend). Blue and purple lines indicate IQR of AE inclusion frequencies for all mutated and wt minigenes,
respectively. Sequence of wt RON minigene given below. g Isoform frequencies arising from mutations along RON minigene. Stacked bar chart shows
median frequency of six isoform categories for all minigenes with mutation at a given position. Average of three biological replicates in HEK293T cells.
Asterisks highlight positions where mutations lead to non-canonical isoforms depicted in b
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Fig. 2 A linear regression model determines more than 1900 single mutation effects. a Model-based inference of single mutation effects. Isoform
quantiﬁcations from RNA-seq for 5598 unique minigene variants, each harbouring multiple mutations, are used as input. A kinetic model of splicing
reactions reveals that splice isoform ratios show linear mutation effects, irrespective of other mutations. A linear regression model is used to infer single
mutation effects in a system of 5010 linear equations, one per mutated minigene variant. b Regression model describes experimental measurements with
high correlation (Pearson correlation coefﬁcient r= 0.99, P value <2e−16). Scatterplot shows frequencies of distinct splice isoforms (see legend;
separately shown in Supplementary Fig. 5a) for combined mutations calculated from ﬁtted model against one biological replicate (see Supplementary
Note 2). c The model more accurately infers frequently occurring single mutation effects. Cross-validation by separately excluding single-mutation
minigenes (and permutations of other minigenes containing this mutation). Inference is expressed as standard deviation of inference error in AE inclusion
(y-axis) and analysed for different permutations containing mutation at different frequencies (x-axis). Inference power of model (black dots) matches
theoretical expectation (green line) and outperforms median-based estimation (grey dots; see Supplementary Note 2). d Experimental validation of model-
inferred single mutation effects. Semiquantitative RT-PCR measurements of AE inclusion (other isoforms in Supplementary Fig. 4b) for targeted single-
mutation minigenes that were not used for model ﬁtting. Discrepancies between model and data appear if mutation infrequently occurs in the library
(colour-coded). r, Pearson correlation coefﬁcient and associated P value. e Model-inferred landscapes of 1747 single mutation effects on AE inclusion, AE
skipping and full IR in HEK293T cells. Each mutation effect is indicated as a coloured dot (inserted nucleobase, see legend). Red lines indicate median
(dashed) ± 2 standard deviations (SD; solid) for wt minigenes. f, g Zoom-in landscapes of single mutation effects on AE inclusion around 3′ splice site of
RON exon 11 (f) and on full IR around 5′ splice site of constitutive exon 10 (g). Black lines and arrowheads mark splicing signals, including branch point,
polypyrimindine tract (Py-tract) and splice sites. Visualisation as in e
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strength upon mutation29 (Spearman correlation coefﬁcient r=
0.89, P value= 2.36e−08; Supplementary Fig. 9a). In contrast,
predictions for 3′ splice site strength capture the effects of Py-
tract composition, but fail to detect branch point mutations and
other sequence contributions (Spearman correlation coefﬁcient
r= 0.62, P value= 4.02e−07; Supplementary Fig. 9b). As
expected, transitions between pyrimidines within the Py-tract
upstream of RON exon 11 act neutrally, whereas transversions
into purines reduce inclusion, illustrating that the screen allows to
discriminate base-speciﬁc effects (Fig. 2f). Consistent with the
exon deﬁnition model of splicing, we ﬁnd that disrupting the 5′
splice site of constitutive exon 12 (not spliced in the minigene
context) also changes AE inclusion (Fig. 2e, Supplementary
Table 2 and Supplementary Data 4), underlining that ﬂanking
constitutive exons can distally inﬂuence alternative splicing11,30.
Notably, 91% of all positions within RON exon 11 (134/147 nt)
harbour at least one splicing-effective mutation, revealing that the
alternative exon is densely packed with cis-regulatory elements
(Fig. 2e and Supplementary Fig. 8). Moreover, neighbouring
positions or even different base substitutions in the same
positions often affect different isoforms or change splicing in
opposite directions (e.g., regions 404–429 nt or 565–567 nt,
respectively, in Supplementary Data 4). The resulting patterns
likely resemble footprints of the RNA sequence speciﬁcity of the
interacting RBPs (see below) or RNA secondary structures. In
addition to disrupting existing cis-regulatory elements, some
mutations may also generate new elements, which further
increases the complexity of the observed regulatory landscape.
The widespread occurrence of splicing-regulatory effects in
RON exon 11 highlights that the majority of exonic positions
mediate splicing regulation and thus harbour a second layer of
information beyond their protein-coding function. As previously
described16, splicing-regulatory effects occur with similar fre-
quency and effect sizes for synonymous and non-synonymous
mutations (Supplementary Fig. 9e, f). Moreover, we detect
substantial effects in the ﬂanking introns and constitutive exons
(50–82% splicing-effective positions per region; Supplementary
Table 2). Albeit less frequent, the splicing-effective mutations
within introns show comparable effect sizes to those in the
alternative exon (Supplementary Fig. 9d). Globally, mutations in
and around the alternative exon primarily affect the AE inclusion
and skipping isoforms, whereas mutations in the downstream
constitutive exon strike a balance between AE inclusion and full
intron retention (Supplementary Fig. 8).
In line with a pathological relevance, we ﬁnd that splicing-
effective positions within introns are more conserved than non-
effective positions, evidencing an evolutionary selection pressure
towards maintaining the splicing-effective positions31 (Supple-
mentary Fig. 9c). In contrast, within exons both splicing-effective
and non-effective positions show high conservation but no
difference, likely reﬂecting constraints on amino acid composi-
tion that may overrule conservation of splicing signals. A total of
135 (25%) of splicing-effective mutations within the three exons
are synonymous with respect to the encoded RON protein and
would hence not be interpreted as potentially deleterious variants
when considering protein sequence only. Importantly, our results
clearly indicate that albeit preserving the protein sequence, such
synonymous mutations may contribute to disease by changing
alternative splicing patterns32,33.
Splicing-effective positions are mutated in human cancers.
Since altered RON splicing is involved in cancer progression21,25,
we repeated the splicing measurements in the human breast
cancer cell line MCF7. Compared to HEK293T cells, the wt
minigene shows lower AE inclusion in MCF7 cells, supporting a
shift towards the pathophysiological state (Supplementary
Fig. 1b). Nevertheless, the measured mutation effects are highly
consistent between both cell lines, underlining the robustness of
our screening approach (Pearson correlation coefﬁcient r= 0.96,
P value= 2.2e−16; Fig. 3a).
In order to address the physiological relevance of the
mutations, we compared our data to the Catalogue of Somatic
Mutations in Cancer (COSMIC). Out of 33 COSMIC entries
within the region of the RONminigene, 20 coincide with splicing-
effective mutations and seven of these are synonymous with
respect to the encoded RON protein (Fig. 3b). It is thus
conceivable that their splicing-regulatory function rather than
their protein-coding role is involved in cancer progression.
Prompted by this observation, we analysed patient data from The
Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/)
to investigate RON splicing in human cancers. We identiﬁed 153
patients, from 19 different cohorts (representing different cancer
types), that carry mutations in the RON minigene region
speciﬁcally in their tumour samples, but not in their matched
normal samples (Supplementary Data 5). We next quantiﬁed the
difference in RON exon 11 splicing (in PSI), per cohort, between
tumour samples of mutation-bearing and non-bearing patients.
Strikingly, we observe a good correlation between RON splicing
changes in mutated TCGA tumour samples and the single
mutation effects determined by our approach (Pearson correla-
tion coefﬁcient r= 0.62, P value= 4.8e−05; Fig. 3c). Strongest
RON exon 11 skipping associates with a splice site mutation
(G297A; identiﬁed in a patient with thyroid carcinoma, THCA).
Of note, the second largest effect is found for mutation G370T
(head–neck squamous cell carcinoma, HNSC), which introduces
a missense mutation at the level of the encoded protein (Fig. 3d,
see Discussion). The correlation between our screen and the
TCGA data is reduced if these two strongest sites are removed
from the analysis (Pearson correlation coefﬁcient r= 0.27, P
value= 0.12; Fig. 3c), most likely because the remaining effects
are weaker and compromised by experimental variation. In
conclusion, our high-throughput screen recapitulates strong
in vivo splicing changes in human cancer patients.
cis-Regulatory elements in RON are targeted by multiple RBPs.
In MCF7 cells, a total of 1022 mutations across the minigene
affect RON alternative splicing, pointing towards the presence of
multiple cis-regulatory elements (Supplementary Data 6). We
used the ATtRACT database34 to identify putative RBP binding
sites, thereby predicting RBPs that recognise these cis-regulatory
elements. In order to focus on sites that are actively involved in
splicing regulation, we retained only RBP motifs if at least 60% of
the positions therein showed a mutation effect on at least one
splice isoform (referred to as splice-regulatory binding sites,
SRBS). The analysis recovers two previously reported cis-reg-
ulatory elements in the alternative and the downstream con-
stitutive exon that are targeted by HNRNPH26 and SRSF121,
respectively. In total, we identify 76 potential RBP regulators
(Fig. 3e and Supplementary Fig. 10), suggesting that RON splicing
is extensively controlled by multiple RBPs. To prioritise among
them, we overlaid our data with a large-scale knockdown (KD)
screen which tested the KD effect of 31 RBPs from our list on
RON exon 11 splicing in HeLa cells35. Notably, 17 of these RBPs
showed a substantial impact on RON splicing, with HNRNPH
and SRSF2 being the strongest repressor and activator, respec-
tively (Fig. 3e).
In a complementary approach, we investigated the expression of
190 RBPs which were identiﬁed as putative regulators of RON
splicing by our ATtRACT analyses and/or by the published RBP
KD screen35 using matched RNA-seq data sets for 4514 TCGA
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cancer patient samples from 27 different cancer types. We detect
140 RBPs whose transcript levels signiﬁcantly correlated with RON
exon 11 inclusion (FDR for Spearman correlation <5%; Supple-
mentary Fig. 11a–c and Supplementary Data 7). Compared to all
annotated RBPs or all protein-coding genes, the 190 pre-selected
RBPs signiﬁcantly enriched among the most highly correlated (gene
set enrichment analysis, P value= 0.04 or 0.003, respectively).
Strikingly, the strongest association in the TCGA data set is
observed for HNRNPH2, whose expression shows a signiﬁcant
negative correlation with RON exon 11 inclusion (Spearman
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Pearson correlation coefﬁcient and associated P value. r= 0.27, P value= 0.12 without two mutations with strongest impact (G370T and G297A).
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transcripts per million, TPM) and RON exon 11 PSI across all TCGA tumour samples. r, Spearman correlation coefﬁcient and associated P value
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correlation coefﬁcient r=−0.27, P value < 2e−16; Fig. 3f). This
behaviour is consistent with the previously described function of
HNRNPH as a repressor of RON exon 11 inclusion26.
Differentiating into the 27 TCGA cohorts, we observe a
signiﬁcant correlation in 11 individual cancer types (FDR for
Spearman correlation < 5%; Supplementary Table 3), all negative,
suggesting that HNRNPH2-mediated repression of RON exon 11
commonly occurs in human cancers. Notably, we ﬁnd a similar
association in RNA-seq data of 24 healthy human tissues from
the Genotype-Tissue Expression (GTEx) Project36 (Spearman
correlation coefﬁcient r=−0.12, P value= 5.7e−11; Supplemen-
tary Fig. 11d). Comparing GTEx and TCGA samples, we observe
consistently lower RON exon 11 inclusion levels in the tumour
samples (mean PSI 76% vs. 67%, P value < 2.2e−16,
Mann–Whitney–Wilcoxon test), supporting an increased expres-
sion of the constitutively active RONΔ165. Accordingly,
HNRNPH2 expression is increased in cancer (mean transcripts
per million [TPM] 57.88 vs. 46.29, P value < 2.2e−16;
Mann–Whitney–Wilcoxon test). Together, these observations
suggest that HNRNPH is a major determinant of RON alternative
splicing in healthy human tissues and cancer.
HNRNPH binding can both activate and repress RON splicing.
Within the RON minigene, we predict 22 SRBS for HNRNPH
(Fig. 4a), all of which harbour the G-rich sequences (G-runs)
recognised by HNRNPH37. The HNRNPH SRBS occur across all
transcript regions and arrange into ﬁve clusters, each containing
at least three SRBS (clusters 1–5, Fig. 4a). Individual-nucleotide
resolution UV crosslinking and immunoprecipitation (iCLIP;
Supplementary Fig. 12a) in HEK293T cells conﬁrms that endo-
genous HNRNPH signiﬁcantly binds at the predicted HNRNPH
SRBS clusters (Fig. 4a and Supplementary Fig. 12b), with the
exception of cluster 4. The strongest iCLIP signal locates in the
alternative exon (Supplementary Fig. 12b).
Consistent with HNRNPH’s sequence preference towards G-
runs, mutations within the binding sites show opposing impact
when either disrupting or generating G-runs in the RNA
sequence (Fig. 4b). The direction and the most susceptible
isoform depend on the position of the HNRNPH SRBS. Most
prominently, mutations within SRBS cluster 3 in the alternative
exon promote inclusion (Fig. 4c). A similar splicing pattern is
observed for the wt RON minigene upon HNRNPH KD (Fig. 4d),
a
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indicating that cluster 3 plays an important role in HNRNPH-
mediated repression of RON exon 11. Mutations in the intronic
clusters 2 reduce AE inclusion, whereas mutating cluster 5 in the
downstream constitutive exon 12 leads to decreased intron
retention, accompanied by increased AE skipping. These
observations cumulate into a complex regulatory scenario, in
which HNRNPH acts via multiple binding sites that have
activating or repressing effects on RON splicing.
Synergy analysis identiﬁes predominant HNRNPH sites. In
order to identify which sites are most relevant for HNRNPH-
dependent regulation, we tested the splicing response of the
minigene library upon HNRNPH KD. We hypothesised that
mutations that either weaken or reinforce an HNRNPH binding
site would display positive or negative synergy with the
HNRNPH KD. For instance, a reduced KD response compared
to the wt minigene would be expected if an important
HNRNPH binding site is compromised by a mutation (negative
synergy).
In order to test this idea, we performed siRNA-mediated
HNRNPH KD in MCF7 cells expressing the minigene library and
used targeted RNA-seq to measure the splicing outcome. As
previously reported26,35, HNRNPH KD results in a strong
increase in RON exon 11 inclusion for both wt and mutated
minigene variants in the library. In line with synergy, a subset of
minigene variants reproducibly show a weaker or stronger KD
response compared to the remainder of the library. For instance,
minigenes harbouring mutations G305A or G310A within cluster
3 consistently show elevated control AE inclusion levels, but a
reduced KD response, suggesting that HNRNPH regulation is
partially abolished due to these mutations (Fig. 5a).
To comprehensively identify synergistic interactions, we
again turned to linear regression modelling and inferred the
single mutation effects in control and KD conditions (Fig. 5b).
We then calculated a z-score, in which the difference in the KD
effect between wt and mutant is normalised by the experimental
variation of the wt minigenes. Using our model based on
isoform ratios (Supplementary Note 3 and Supplementary
Fig. 13), we estimate that the HNRNPH KD on average has a
2.4-fold effect on the AE skipping-to-inclusion isoform ratio.
Importantly, this effect is largely independent of the mutational
background and hence the AE inclusion frequency which a
minigene exhibits under control conditions (Fig. 5b, right). The
exception are very strong mutations that on their own
completely abolish splicing, i.e., prevent the KD from having
additional measurable effects (Supplementary Fig. 7f, g). In
contrast, at the level of individual splice isoform frequencies,
the KD effect of all mutations strongly depends on the starting
isoform level and thereby introduces systematic biases (Fig. 5b,
left, and Supplementary Fig. 7e). Since such biases can be
minimised by modelling splice isoform ratios, our approach
allows to reliably estimate synergy.
By modelling the splice isoform ratios, we derive landscapes of
synergistic interactions between HNRNPH KD and distinct
mutations in the RONminigene sequence (Fig. 5c, Supplementary
Fig. 12c and Supplementary Data 6). For the vast majority of
point mutations, no signiﬁcant synergistic interaction is observed
(1428 out of 1786, 80%; Supplementary Table 2). Importantly,
354 mutations (20%) in 278 positions show signiﬁcant synergy
for at least one splice isoform (|z-score| > 2, adjusted P value <
0.001, Stouffer’s test). These are signiﬁcantly enriched in the SRBS
in cluster 3 in the alternative exon, in which 64% of mutations
(93% of positions) display synergy with HNRNPH KD (Fig. 5d
and Supplementary Fig. 12c, d). This observation suggests that
the SRBS in the alternative exon are most relevant for HNRNPH-
dependent regulation. This is further supported by the fact that
42% of the strongest synergistic interactions that affect AE
skipping (|z-score| > 5) fall into SRBS cluster 3 (Fig. 5c).
Consistent with the known sequence preference of HNRNPH,
we observe that the disruption of G-runs in cluster 3 leads to a
weaker KD response (negative synergy; Fig. 5d and Supplemen-
tary Fig. 14). Instead, synergistic interactions at clusters 1 and 5 in
the constitutive exons frequently reinforce HNRNPH-dependent
regulation by creating new or extending existing G-runs, leading
to a stronger-than-average KD response (positive synergy;
Supplementary Fig. 14). Hence, while the HNRNPH SRBS
clusters outside RON exon 11 do not prevail under the tested
conditions, they can become more important when HNRNPH
binding for these sites is increased.
In order to validate the functional relevance of SRBS cluster 3,
we generated ten minigene variants with individual point
mutations disrupting G-runs within HNRNPH SRBS from the
ﬁve clusters (Supplementary Data 8), and tested their splicing
under HNRNPH KD conditions using semiquantitative RT-PCR.
Indeed, single mutations in cluster 3, for which the model had
inferred the strongest synergistic interactions, almost completely
cancel out the KD response (Fig. 5e). In contrast, minigenes with
mutations in other clusters still respond to the HNRNPH KD, in
agreement with their less pronounced synergistic interaction with
HNRNPH. In summary, the synergy analysis allows to link an
RBP to its functionally most relevant cis-regulatory elements.
Cooperative HNRNPH binding establishes a splicing switch.
We ﬁnd that individual G-run-disrupting point mutations within
the alternative exon (e.g., G305A, G331C and G348C) are sufﬁ-
cient to almost completely abolish the response to HNRNPH KD
(Fig. 5e). This suggests that the corresponding SRBS cooperatively
recruit HNRNPH. In line with this notion, our linear regression
model which does not consider cooperativity, on average provides
a worse ﬁt to minigenes containing simultaneous mutations in
two HNRNPH SRBS in the alternative exon (Supplementary
Fig. 15e). In order to test for interdependent HNRNPH binding,
we repeated the HNRNPH iCLIP experiments in the context of
mutated RON minigenes harbouring point mutations within
three different SRBS of cluster 3. In line with cooperative binding,
the resulting drop in HNRNPH crosslinking is not limited to the
site of the point mutation, but spreads to several further SRBS in
RON exon 11 (Fig. 6a).
Cooperative HNRNPH binding to multiple SRBS would imply
that HNRNPH regulates splicing with a steep, sigmoidal
dose–response curve. To test this, we performed gradual
HNRNPH KD and HNRNPH1 overexpression experiments, in
which we transfected MCF7 cells with increasing amounts of
HNRNPH-speciﬁc siRNA and HNRNPH1 overexpression con-
struct, respectively. Notably, we observe a switch-like splicing
response of RON exon 11 from the minigene as well as the
endogenous RON gene. Indicative of strong cooperativity, we ﬁnd
that the dose–response curves can be described by high Hill
coefﬁcients for the endogenous RON gene (nH= 17.4, conﬁdence
interval (CI) [10.8,35.2]) as well as the transfected wt RON
minigene (nH= 13.8, CI [10.4,17.7]; Fig. 6b and Supplementary
Figs. 15a–d, 16). Consistently, we observe that HNRNPH2 shows
the steepest regression slope among the 190 RBPs tested for
expression correlation in the TCGA data (Figs. 3f and 6c). Even
though HNRNPH2 expression in the TCGA data is not variable
enough to reach plateaus in splicing, the steep slope further
supports a switch-like behaviour of RON exon 11 inclusion.
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Based on these observations, we conclude that RON exon
11 splicing is extensively regulated via multiple interdependent
HNRNPH binding sites that exert strong cooperativity. This
enables switch-like splicing with small changes in HNRNPH
concentration causing large changes in splicing (Fig. 6d),
potentially explaining why HNRNPH expression is a strong
predictor of RON exon 11 splicing in cancer cells.
Discussion
Systems approaches combined with mathematical modelling are
required to fully comprehend the complex regulation of alter-
native splicing. Our work builds on previous approaches to
measure the effect of mutations in deﬁned regions of splicing-
reporter minigenes16–18,38. Central to our analytical framework is
the mathematical splicing model which allows us to predict the
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effects of individual mutations based on measurements of com-
bined mutation effects. We employ linear regression modelling to
disentangle these effects, and validate the predictive power of this
approach using cross-validation, targeted single mutations and by
relating RON mutations to splicing outcomes in cancer patients.
To formulate the linear regression model, we investigated how
mutation effects cumulate in minigenes exhibiting several muta-
tions. We termed a mutation effect linear if a mutation induces
the same fold change in splicing irrespective of the mutational
background (i.e., other mutations being present). If linearity holds
true, the mutation effects add up in log-space and a linear
regression can be performed to infer single mutation effects from
the measured combined mutations. Using a kinetic model
reﬂecting RON alternative splicing, we found that splice isoform
ratios show the desired linear behaviour (Supplementary Note 1
and Supplementary Fig. 7e). Accordingly, the isoform ratio-based
regression model ﬁtted the complete minigene library with high
accuracy. In line with our approach, Rosenberg et al. quantita-
tively modelled the contribution of randomised k-mer sequences
in 25-nt regions of a synthetic minigene using an additive model
that was based on the AE inclusion-to-skipping ratio18. In con-
trast, direct linear regression using the splice isoform frequencies
decreases the accuracy and inference power of the model (Sup-
plementary Note 2 and Supplementary Fig. 7b), possibly indi-
cating nonlinear interactions between mutations at this level.
Therefore, care needs to be taken when interpreting the interplay
of mutations and/or other perturbations directly based on the
abundance of certain splice isoforms (e.g., percent spliced-in/PSI,
or equivalent metrics), as each perturbation shifts the operating
point of the system. As a global trend, we observe that minigenes
showing inclusion frequencies around 50% are most sensitive to
perturbations such as HNRNPH knockdown (Fig. 5a). However,
after transformation to isoform ratios, HNRNPH knockdown
elicits linear, context-independent changes (Fig. 5b). Thus, iso-
form ratios are superior when analysing the interplay of multiple
treatments or mutations, while isoform frequencies are essential
for judging the physiological impact of splicing changes.
Our conclusion that combined mutations can be accurately
described as a linear combination of single point mutations
implies that synergistic interactions between mutations have only
a minor impact on RON splicing outcomes. Intriguingly, our data
suggest that even simultaneous mutations in two cis-regulatory
elements mostly elicit linear, independent effects: across more
than 100 minigenes containing two or more simultaneous
mutations in any HNRNPH SRBS, 93% of the splice isoform
frequencies can be explained within 5% deviation from the
measured value using the linear regression approach (Supple-
mentary Fig. 15e). Thus, the goodness of ﬁt of this subset is
comparable to the complete minigene population, suggesting that
cis-regulatory elements in many cases act independently on RON
alternative splicing.
Despite most mutations acting independently, we observe
cooperative effects for adjacent HNRNPH binding sites in the
alternative exon (see below). Such nonlinear effects are not cap-
tured by our model, but are in line with previous work showing
that splicing-relevant mutations can amplify each other in com-
bination, thereby showing cooperative interactions11,16. That
such nonlinear effects are more prevalent in a previous screen by
Julien et al.16 may result from the fact that their study system-
atically screened double mutations in close vicinity. However,
when relating the goodness of ﬁt of our linear regression model to
the nearest distance between two splicing-effective mutations, we
found no clear effect of the mutation proximity on the ﬁtting
error (Supplementary Fig. 7c, d). This suggests that also nearby
mutations typically act independently of each other and agrees
well with results from a recent saturation mutagenesis study of a
51-nt region in the alternatively spliced exon of the WT1 gene17.
Since our data set does not exhibit enough coverage to compre-
hensively detect cooperative interactions of nearby mutations, it
remains possible that adjacent sites mutually inﬂuence each other,
whereas distal cis-regulatory elements act independently. Such a
scenario would be consistent with a local assembly of ribonu-
cleoprotein complexes that act as independent regulatory units.
Our high-throughput mutagenesis screen uncovers a highly
complex cis-regulatory landscape, with >80% of all positions
affecting RON alternative splicing. Within this set, we recover
mutations in all previously identiﬁed cis-regulatory ele-
ments7,21,26,27,39. Within the alternative RON exon 11, we ﬁnd
that 91% of all positions show a signiﬁcant impact on RON
splicing. Conceptually, these splicing-effective mutations either
disrupt existing cis-regulatory elements at the RNA sequence or
structure level or generate novel elements, thereby further
increasing the complexity of RON splicing regulation. Even
though the newly generated cis-regulatory elements do not occur
under normal conditions, they may be relevant in cancer when
mutations accumulate. A similar density of effective mutations
was also reported for FAS exon 616. Our study demonstrates that
other than previously suggested, such a densely packed
Fig. 5 Synergistic interactions highlight the functionally most relevant HNRNPH binding sites. a Minigene variants are differentially spliced upon HNRNPH
knockdown (KD). Scatterplot compares AE inclusion under control (ctrl) and HNRNPH KD conditions for all minigene variants. Average behaviour
illustrated by running mean and standard deviation (red). Shadings schematically highlight stronger/weaker-than-average KD response. Minigenes with
mutations C307G, G310A and G305A in HNRNPH splice-regulatory binding sites (SRBS) cluster 3 are highlighted. b Quantiﬁcation of synergistic
interactions by linear regression modelling. Single mutation effects are determined separately for ctrl and HNRNPH KD using linear regression and
subtracted to estimate KD responses compared to wt (z-score based on standard deviation of wt minigenes, colour-coded; see Supplementary Note 3).
Right graph shows model-inferred AE skipping-to-inclusion isoform ratios of single mutations in ctrl vs. KD. Regression line indicates average KD effect.
Consideration of isoform ratios, as compared to isoform frequencies (a), leads to linearisation of KD response in line with predictions of kinetic splicing
model (Supplementary Fig. 3a). c Model-inferred synergistic interactions accumulate in RON exon 11. Bar diagrams quantify signiﬁcant synergistic
interactions affecting AE skipping-to-inclusion isoform ratio using different z-score cutoffs in adjacent 5-nt windows. Line indicates density in 5-nt sliding
window. Splice sites ± 2 nt were excluded. Predicted HNRNPH SRBS (brown) are given above. dMutations in HNRNPH SRBS cluster 3 lead to increased AE
inclusion and reduced HNRNPH KD response. Dot plots (top) display single mutation effects (inserted nucleobase, see legend) on AE inclusion (mean, n=
3). Red lines indicate median isoform frequency of wt minigenes ± 2 standard deviations (SD). HNRNPH SRBS (brown) are given above. Heat maps
(bottom) show z-scores as measure of synergy (mean, n= 3) per inserted nucleobase. White or grey ﬁelds indicate mutations that were not present or
ﬁltered out, respectively (see Methods). Purple boxes highlight signiﬁcant synergistic interactions (0.1% FDR). e Consistent with strong synergistic
interactions (colour-coded), mutations in cluster 3 almost completely abolish the HNRNPH KD response in MCF7 cells. Scatterplot compares model-
inferred estimates with semiquantitative RT-PCR measurements of AE inclusion (circles) and AE skipping (triangles) upon HNRNPH KD (mean, n= 3) for
ten targeted mutations in HNRNPH SRBS (Supplementary Data 8)
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arrangement is not exclusive to short exons such as FAS exon 616
(63 nt) or SMN1 exon 738 (54 nt), as RON exon 11 (147 nt) is
around the average length of human cassette exons40.
A major advance of our study is that we detect cis-regulatory
elements along the entire minigene, including introns and
ﬂanking constitutive exons. In the constitutive exons, the effect
sizes are generally smaller, possibly due to an accumulation of
partially redundant exonic splicing enhancers (ESEs) that ensure
constitutive splicing13. Notably, we ﬁnd that mutations not
necessarily trigger intron retention, but can also speciﬁcally swap
between AE inclusion and skipping (such as T581G or G686C;
Supplementary Data 6). These distal effects agree with previous
observations from positional splicing maps (RNA-maps), show-
ing that RBP binding at ﬂanking constitutive exons can regulate
the inclusion of neighbouring alternative exons41.
Our ATtRACT analysis together with a previous study35 sug-
gest that splicing of RON exon 11 is controlled by a multilayered
network of at least 17 trans-acting RBPs. Many of these RBPs are
linked to multiple binding sites in different regions, further
increasing the regulatory complexity. Importantly, signiﬁcant
correlations in our TCGA analyses suggest that many of the
regulatory relationships are functional in humans in vivo. A
multilayered regulation of alternative splicing events has also
been suggested by a recent high-throughput screen for RBP KD
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effects42. We extend beyond this view by directly identifying
synergistic interactions between sequence mutations and RBP
KD.
Our study highlights HNRNPH as a key regulator of RON exon
11 splicing. Using mutational analysis and iCLIP, we demonstrate
that it acts via ﬁve clusters of intronic and exonic SRBS that
antagonistically affect RON splicing (Fig. 6d). In line with pre-
vious global splicing maps37,43,44, we observe that HNRNPH
binding in the alternative exon represses AE inclusion, whereas
binding in the ﬂanking introns increases AE inclusion. Synergy
analysis pinpoints the SRBS in the alternative exon as the func-
tionally most relevant sites. We speculate that this interwoven
arrangement of antagonistic SRBS may allow to ﬁne-tune RON
splicing. More generally, tightly regulated exons might beneﬁt
from modulating not just one but several competing splicing
reactions in order to achieve an optimal adjustment of alternative
splicing under changing physiological conditions.
Other than previously suggested for intronic HNRNPH sites44,
we ﬁnd strong indications for cooperative binding of HNRNPH
to multiple SRBS within the alternative exon. One possible
mechanism for the observed cooperativity would be oligomer-
isation of HNRNPH via its glycine/tyrosine (GY)-rich domain. It
was recently shown that other hnRNP proteins form multimeric
assemblies via GY-rich domains to regulate splicing45. Moreover,
HNRNPH binding sites might fold into G-quadruplex struc-
tures46–49, which could contribute to the observed cooperativity
through sequestering and simultaneously releasing G-runs. The
cooperative HNRNPH binding renders RON splicing sensitive to
individual mutations in HNRNPH SRBS or to small changes in
HNRNPH protein expression.
Extensive changes in alternative splicing are characteristic for
many human cancers50, and it has been estimated that about half
of all synonymous driver mutations change splicing51. The
skipping of RON exon 11 results in a ligand-independent, con-
stitutively active variant of the encoded RON receptor tyrosine
kinase, RONΔ16520. Contrary to initial reports52, we and others
detect RONΔ165 expression also in healthy human tissues21,
suggesting that the encoded protein could play a role under
physiological conditions. However, overexpression of RONΔ165
was shown to trigger increased cell motility and invasive
tumourigenesis20. Consistent with this oncologic potential,
abnormal RONΔ165 accumulation has been described in breast
and colon cancers, among others25.
With the help of our mutagenesis screen, we identify many
mutations that trigger a strong skipping of RON exon 11.
Importantly, the mutation effects in our screen are reﬂected in
cancer patients bearing the same mutations. Several of the
mutations are synonymous with respect to the encoded protein,
suggesting that mutation-induced splicing changes can have
deleterious impact in cancer51,53–55. In addition, we also identify
numerous non-synonymous mutations that have a strong, and in
some cases a surprising, impact on splicing regulation: for
instance, the nonsense mutation G370T found in a head–neck
squamous cell carcinoma (HNSC) patient also triggers RON exon
11 skipping (Fig. 3c, d). Intriguingly, this splicing change inverts
the physiological consequence of the mutation, as the majority of
mature RON transcripts will exclude the mutated exon and
thereby translate into a constitutively active rather than a pre-
maturely truncated RON protein.
Due to their prevalence in cancers, altered RON isoforms
represent a promising target for intervention56. For instance,
clinical trials assessed the therapeutic potential of monoclonal
antibodies targeting RON to block the binding of its ligand MSP
(MST1)57 (ClinicalTrials.gov Identiﬁer: NCT01119456; antibody
RON8, Narnatumab, ImClone; phase-I discontinued). However,
tumours expressing the constitutively active isoform RONΔ165
can speciﬁcally escape this kind of therapies, as this protein
no longer requires ligand-dependent activation24. A detailed
knowledge of mutations that promote this isoform might there-
fore allow a personalised therapy in the future.
Methods
Cloning of the RON wt minigene. To generate the RON wt plasmid, a segment of
the MST1R gene was ampliﬁed by polymerase chain reaction using Phusion DNA
polymerase (NEB) with the forward primer 5′- CCCAAGCTTTGTGAGAGGCA
GCTTCCAGA-3′ and the reverse primer 5′- CAGTCTAGANNNNNNNNNNNN
NNNGGATCCGCCATTGGTTGGGGGTAGGGGCTGATTAAAGGTAGG-3′ at
65 °C annealing temperature with human genomic DNA (Promega) as a template
(Supplementary Table 4). The 779 bp DNA product was gel-puriﬁed with the
QIAquick Gel Extraction Kit (QIAGEN) and then digested using HindIII and XbaI
restriction endonucleases (NEB). The cut DNA fragment was puriﬁed using a PCR
puriﬁcation kit (QIAGEN) prior to ligation into the pcDNA 3.1 (+) vector
(Invitrogen). To raise AE inclusion in the RON wt minigene comparable to
endogenous levels, the ﬁrst nucleotide of the alternative exon was exchanged to a
guanine.
Plasmids harbouring point mutations were generated using the Q5 Site-
Directed Mutagenesis Kit (NEB) according to the manufacturer’s instructions.
Mutagenic PCR and library construction. For the mutagenesis of the RON
minigene, we used the GeneMorph II Random Mutagenesis Kit (Agilent) according
to the manufacturer’s instructions. Aiming for an average mutation rate of 3.5
mutations/minigene, three libraries were independently generated and ﬁnally
fused. To this end, 8 and 4 µg of the unmutated RON wt plasmid were ampliﬁed
with 30 cycles, and 0.8 µg of the unmutated RON wt plasmid were ampliﬁed with
20 cycles. The primers used to amplify the mutagenic fragments were 5′-CCCAA
GCTTTGTGAGAGGCAGCTTCCAGA-3′ (forward primer) and 5′-CAGTCTAG
ANNNNNNNNNNNNNNNGGATCCGCCATTGGTTGGGGGTAGGGGCTGA
TTAAAGGTAGG-3′ (reverse primer) (Supplementary Fig. 1a and Supplementary
Table 4). The PCR products were puriﬁed using the QIAquick Gel Extraction Kit
(QIAGEN). Puriﬁed DNA was cut with HindIII and XbaI (NEB) restriction
endonucleases for 45 min at 37 °C and subsequently puriﬁed using a PCR
Fig. 6 Cooperative HNRNPH binding establishes a splicing switch of RON exon 11. a A single point mutation in an HNRNPH splice-regulatory binding site
(SRBS) results in reduced HNRNPH binding in HEK293T cells also at neighbouring SRBS in RON exon 11. Bar diagrams show the number of HNRNPH iCLIP
crosslink events on the wt RON minigene (top) and the difference in normalised crosslink events on wt and mutated RON minigenes (mutations G305A,
G331C and G348C in different SRBS within cluster 3, marked by dashed lines; bottom) in a sliding 5-nt window along the wt RONminigene. HNRNPH SRBS
(brown boxes) indicated below. b Splicing response to gradual HNRNPH KD and overexpression suggests cooperative regulation of RON exon 11 by
HNRNPH. Scatterplot shows semiquantitative RT-PCR quantiﬁcations of RON exon 11 inclusion (in percent spliced-in/PSI, Supplementary Fig. 15a, b) from
endogenous RON gene (orange) and wt RON minigene (blue) against corresponding HNRNPH protein levels (Supplementary Fig. 15c, d). Degree of
cooperativity is quantiﬁed by ﬁtting Hill equation (solid lines) and compared to theoretical ﬁt for non-cooperativity (dashed line). Error bars denote
standard deviation of three biological replicates. c Steep regression slope for HNRNPH2 supports cooperative HNRNPH regulation and switch-like splicing
of RON exon 11. Boxplot shows distribution of regression slopes for expression correlations of 190 RBPs with RON exon 11 inclusion in TCGA samples
(Supplementary Data 7). Box represents quartiles, centre line denotes 50th percentile and whiskers extend to most extreme data points within 1.5×
interquartile range. HNRNPH2 is highlighted. d HNRNPH acts as key regulator of RON splicing by recognising multiple cis-regulatory elements in a
cooperative fashion. Schematic model summarises position-dependent effects of HNRNPH on RON exon 11, indicating most strongly effected isoform for
each site (left panel). Multiple interdependent HNRNPH binding sites within RON exon 11 exert strong cooperative control on the alternative exon, resulting
in a splicing switch upon small changes in HNRNPH abundance (right panel)
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puriﬁcation kit (QIAGEN). The digested plasmid DNA and mutagenic fragments
were ligated for 5 min at room temperature in a volume of 21 µl containing 50 ng of
plasmid and 21 ng of insert (3:1 ratio of insert to plasmid DNA), 10 µl of 2× Quick
Ligation Reaction Buffer and 1 µl Quick T4 DNA ligase (NEB). Transformations
were carried out via CaCl2 transformation of Escherichia coli DH5-alpha strain
with 2 µl of the ligated DNA. Bacteria were plated in low density to allow the
formation of similar-sized colonies and determination of the number of transfor-
mants by counting of the colonies. Sixteen hours after the transformation, ~2000
colonies per transformation were washed off the plates into lysogeny broth (LB)
medium and plasmids were extracted using the Plasmid Plus Midi Kit (QIAGEN).
In addition, 200 wt plasmids were generated to be used as a spike-in to the above-
mentioned libraries by using the same primers and template wt plasmid but non-
mutagenic ampliﬁcation with Phusion DNA Polymerase (NEB) and the following
conditions: 98 °C for 30 s, 30 cycles of [98 °C for 10 s, 61 °C for 20 s, 72 °C for 20 s]
and ﬁnal extension at 72 °C for 5 min. Note that the remainder of wt minigenes in
the library represent the proportion of error-free minigenes within the product
pool of the mutagenic PCR. Puriﬁcation, digestion and transformation were per-
formed as described above. Mutagenesis and wt libraries were pooled together to
yield a library of ~6000 plasmids. To obtain single plasmids of the library for
benchmarking via Sanger Sequencing and validation via RT-PCR, a re-
transformation of the library was carried out and plasmids of resulting colonies
were extracted using QIAprep Spin Miniprep Kit (QIAGEN).
Semiquantitative RT-PCR. Semiquantitative RT-PCR was used to quantify iso-
form ratios of individual plasmids and endogenous RON mRNA. To this end,
reverse transcription was carried out in a volume of 20 µl using 500 ng of total
RNA, 1 µl (dT)18 primer (100 µM), 1 µl dNTPs (10 mM) and 1 µl RevertAid reverse
transcriptase (Fermentas) by heating 70 °C for 5 min, 25 °C for 5 min, 42 °C for 60
min, 45 °C for 10 min, and 70 °C for 5 min. Subsequently, 1 µl of the cDNA was
used as a template for the PCR reaction with the condition as follows: 94 °C for 30
s, 24 cycles (minigene) or 35 cycles (endogenous) of [94 °C for 20 s, 52 °C (mini-
gene) or 62 °C (endogenous) for 30 s, 68 °C for 30 s] and ﬁnal extension at 68 °C for
5 min. The primers used to amplify the minigene-derived isoforms anneal to the
upstream constitutive exon and a region located downstream of the random bar-
code but upstream of the polyadenylation site: 5′- TGCCAACCTAGTTCCAC
TGA-3′ (forward primer) and 5′- GCAACTAGAAGGCACAGTCG-3′ (reverse
primer). The primers to amplify endogenously derived isoforms were 5′-CCTGA
ATATGTGGTCCGAGACCCCCAG-3′ (forward primer) and 5′-CTAGCTGCT
TCCTCCGCCACCAGTA-3′ (reverse primer; Supplementary Table 4). The
TapeStation 2200 capillary gel electrophoresis instrument (Agilent) was used for
isoform quantiﬁcation of the PCR products.
Cell culture and transfection of plasmids and siRNAs. HEK293T and MCF7
cells were grown in Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented
with 10% foetal bovine serum at 37 °C with 5% CO2. Standard HNRNPH KD was
carried out using single small interfering RNA (siRNA) against HNRNPH58 (5′-
GGAGCUGGCUUUGAGAGGA[dT][dT]-3′, Sigma-Aldrich) or non-targeting
control siRNA (5′-UGGUUUACAUGUCGACUAA[dT][dT]-3′, Sigma-Aldrich) at
a ﬁnal concentration of 20 nM. KD efﬁciencies were assessed by western blot
analyses. For gradual HNRNPH KD, the siRNA concentration was varied between
0.05 nM and 10 nM. One day prior to transfection, 2 × 105 HEK293T cells were
seeded in a 6-well plate to result with ~20% conﬂuence at the day of transfection.
MCF7 cells were seeded 3 days prior to transfection with 0.5 × 105 cells per well of a
6-well plate. The transfection mix was prepared by incubating 3 µl RNAiMax
(Invitrogen) with 2 µl siRNA (20 µM) in 200 µl OPTI-MEM (Invitrogen) for 20
min, and the mix was added in a dropwise manner to the cells. For transfection of
plasmids 24 h later, a mixture of 2 µg minigene plasmid DNA and 20 µg poly-
ethylenimine MW ~2500 transfection reagent (Polysciences, Inc.) in 100 µl OPTI-
MEM (Invitrogen) was prepared and incubated for 20 min before it was added to
the cells. Cultures were harvested another 24 h later. For the HNRNPH1 over-
expression, 4 × 105 MCF7 cells were seeded in a 6-well plate 1 day prior to
transfection. Transfection was carried out using Lipofectamine 2000 (Invitrogen)
and 1 or 2.5 µg pcDNA 3.1 (+)-HNRNPH1 overexpression construct or pcDNA
3.1 (+) empty vector control. The minigene plasmid was transfected 24 h later as
described above and cells were harvested another 24 h later. RNA was extracted
using the RNeasy Plus Mini Kit (QIAGEN) according to the manufacturer’s pro-
tocol. For semiquantitative RT-PCR analysis of splicing isoforms without KD
conditions, 7 × 105 HEK293T cells were seeded and transfected the next day with
plasmid DNA under the above-mentioned conditions.
No cell line used in this paper is listed in the database of commonly
misidentiﬁed cell lines maintained by ICLAC. HEK293T (CRL-3216) and MCF7
cells (HTB-22) were purchased from ATCC (Manassas, VA) without further
authentication. Cell lines were tested for mycoplasma contamination on a monthly
basis.
Library preparation and high-throughput sequencing. For preparation of high-
throughput RNA sequencing (RNA-seq) libraries, the total RNA obtained from
transfected HEK293T cells or MCF7 cells was enriched for mRNA by performing
polyA selection of 20 µg of total RNA using Dynabeads® Oligo (dT)25 beads
(Invitrogen) according to the manufacturer’s protocol. Reverse transcription was
carried out using 500 ng of enriched mRNA under the above-mentioned condi-
tions. To prevent the formation of chimeric amplicons, the libraries were ampliﬁed
using emulsion PCR59, with Phusion DNA Polymerase (NEB) and either cDNA
derived from polyA-selected RNA in the case of RNA-seq or plasmid DNA of the
minigene library in the case of high-throughput DNA sequencing (DNA-seq). To
amplify fragments for RNA-seq, the following primers containing Illumina
sequencing adaptors were used (Supplementary Fig. 2g): 5′-CAAGCAGAA-
GACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAA
CCGCTCTTCCGATCTNNNNNNNNNNGTTCCACTGAAGCCTGAG-3′ (for-
ward primer) and 5′-AATGATACGGCGACCACCGAGATCTACACTCTTTC
CCTACACGACGCTCTTCCGATCTNNNNNNNNNNATAGAATAGGGCCCT
CTAGA-3′ (reverse primer) under the following PCR conditions: 98 °C for 30 s, 15
cycles of [98 °C for 10 s, 56 °C for 20 s, 72 °C for 60 s] and ﬁnal extension at 72 °C
for 5 min. For the DNA-seq library ampliﬁcation, the same PCR conditions and 18
cycles with different primer combinations were used (Supplementary Fig. 2a and
Supplementary Table 4). Following ampliﬁcation, the DNA-seq PCR products were
cleaned using the GeneRead Size Selection Kit (QIAGEN) according to the man-
ufacturer’s instructions. Products intended for RNA-seq were puriﬁed using
Agencourt AMPure XP beads (Beckman Coulter). Puriﬁed products were ﬁrst
analysed with the TapeStation 2200 capillary gel electrophoresis instrument
(Agilent) and then ﬂuorimetrically quantiﬁed using a Qubit ﬂuorimeter (Thermo
Scientiﬁc). RNA-seq and DNA-seq were carried out on the Illumina MiSeq plat-
form using paired-end reads of 300 nt length and a 10% PhiX spike-in to increase
sequence complexity.
Western blot. Cell lysates were prepared with modiﬁed RIPA buffer (50 mM Tris
HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% sodium deoxycholate,
protease inhibitor cocktail; Roche). The following antibodies were used for western
blot analyses: rabbit polyclonal anti-HNRNPH, 1:10,000 dilution (AB10374,
Abcam) and mouse monoclonal anti-HNRNPA1, 1:10,000 dilution (R4528, Sigma-
Aldrich).
iCLIP experiment and data processing. We used iCLIP to capture the binding
pattern of HNRNPH on the MST1R transcript. iCLIP was performed according to
a previously published protocol60. In brief, the iCLIP libraries were made from
HEK293T cells 24 h after transfection of the RON wt minigene (in triplicates) or
mutated RON minigenes carrying point mutations G305A (in triplicates), G331C
or G348C (both in duplicates). The cells were irradiated with 150 mJ/cm2 UV light
at 254 nm. For the immunoprecipitation step, we used 7.5 µg of a polyclonal rabbit
anti-HNRNPH antibody from Abcam (AB10374). RNase digestion was performed
by adding 10 µl of 1/100 diluted RNase I (Ambion) to the sample of the wt
minigene experiment shown in Supplementary Fig. 12a or 1/300 diluted RNase I
(Ambion) to each sample of the experiment shown in Fig. 6a (comparison of the
iCLIP landscape of the RON wt minigene with point mutation minigenes). Reverse
transcription was carried out with RT primers listed in Supplementary Table 4. We
performed the sequencing on an Illumina HiSeq 2500 for the RON wt minigene
(51-nt single-end reads) and the RON wt/point mutant minigene comparison was
sequenced on either Illumina MiSeq or NextSeq 500 with 75-nt single-end reads.
Sequencing reads were ﬁrst ﬁltered for quality in the experimental and random
barcode, and then the adaptor sequences were trimmed. Trimmed reads were
mapped to the human genome (hg19/GRCh37) using STAR61 resulting in ~49
million (HiSeq 2500), ~10 million (MiSeq) or ~121 million (NextSeq 500) uniquely
mapping reads. In order to quantitatively compare HNRNPH iCLIP data for the
RON wt and point mutation minigenes (Fig. 6a), crosslink events were normalised
to the total number of crosslink events within the minigene region excluding RON
exon 11. Normalised counts were averaged between replicates, counted into 5-nt
sliding windows and then subtracted between conditions to determine differences
in HNRNPH crosslinking.
DNA-seq data processing and mutation calling. The DNA-seq library was
sequenced on Illumina MiSeq (300-nt paired-end) with a total of 40 million reads
and analysed with a custom Python pipeline (version 2.7.9: Anaconda 2.2.0, 64-bit;
Supplementary Fig. 2b). In detail, we used FastQC (fastqc_v0.11.3; https://www.
bioinformatics.babraham.ac.uk/projects/fastqc/) for quality control and Trimmo-
matic62 (version 0.33; parameters HEADCROP:20 SLIDINGWINDOW: 7:10
MINLEN:0) to remove excess sequence and trim low-quality bases (average Phred
score < 10 in 7-nt window). After trimming, we ﬁltered for a minimum length of
130 nt (read #1) and 90 nt (read #2). In order to extract the 15-nt barcode (read #1)
which assigns the read pairs to an individual minigene variant, we used
matchLRPatterns() from the R/Bioconductor package ‘Biostrings’ to search for the
ﬂanking restriction sites (Lpattern= TCTAGA, Rpattern=GGATCC, allowing
one mismatch). We only retained read pairs with a Phred score ≥ 30 at all barcode
positions. For each minigene variants with at least 640 read pairs, reads were
mapped to the sequence of the RON wt minigene using NextGenMap63 (version
0.4.12). A read was reported as mapped if >50% of its bases were mapped, the
alignment had an identity >65%, and at least one stretch of 13 bp was identical to
the reference. Mutations were called using the HaplotypeCaller tool (version 3.4.0)
of the Genome Analysis Toolkit (GATK)64 with -dt NONE. We recounted
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overlapping reads using bam-readcount (https://github.com/genome/bam-
readcount) and then manually ﬁltered against single-nucleotide variants (SNV)
with low penetrance based on reference (Ref) and alternative (Alt) allele fre-
quencies: (i) Alt/(Alt+ Ref) > 0.8, and (ii) (Alt+ Ref)/total > 0.5 taking into
account all other isoforms. The identiﬁed mutations include 18,948 point muta-
tions as well as 608 short insertions and deletions. The latter were taken into
account as independent sequence variants in the mathematical splicing model and
are provided in addition to the point mutations in Supplementary Data 3. The ﬁnal
library contained 5791 minigene variants, including 591 wt and 5200 mutated
minigenes. The accuracy of mutation calling was validated by Sanger sequencing of
59 randomly selected minigene variants, conﬁrming the presence of all 169 GATK-
called mutations without further false negatives.
RNA-seq data processing and splicing isoform quantiﬁcation. RNA-seq
libraries were sequenced on Illumina MiSeq (300-nt paired-end), yielding 17–22
million reads per sample (Supplementary Table 1), and analysed with a custom
Python pipeline similar to DNA-seq (see above; Supplementary Fig. 2f). Brieﬂy, we
removed low-quality sequences (average Phred score < 20 in 6-nt window) and
extracted the 15-nt barcode (read #1) as described above. Only reads originating
from the 5791 minigene variants that were recovered from the DNA-seq library
were considered for further analyses. Read pairs for each minigene variant were
aligned to the RON wt minigene sequence using the splice-aware alignment
algorithm STAR61 (version 2.5.1b), allowing up to ten mismatches without input of
prior knowledge of existing splice junctions. Only read pairs conferring splice
isoform information (i.e., both mates extended at least 10 nt beyond the con-
stitutive exon boundaries) were kept. Furthermore, all improperly or inconsistently
mapped read pairs were removed from the analysis. Read pairs are referred to as
improperly mapped if they map with a wrong orientation, while inconsistently
mapped read pairs overlap and show a disagreement in their mapping patterns.
Finally, only minigene variants which were covered by at least 100 remaining read
pairs were used further, resulting in 5697, 5645 and 5623 minigene variants
detected in RNA-seq replicates 1, 2 and 3 from HEK293T cells, respectively
(Supplementary Fig. 2h and Supplementary Table 1).
Reconstruction and quantiﬁcation of splicing isoforms. For each read pair, the
underlying splicing isoform was reconstructed based on the CIGAR strings of the two
mates. Isoforms which were supported by <1% of the read pairs or less than two read
pairs in any plasmid were removed from the analysis. The frequency of each isoform
for each minigene variant was calculated as the number of read pairs supporting this
particular isoform in relation to the total read pairs for all detected isoforms for this
particular minigene variant. All kept non-canonical isoforms derived from cryptic
splice site activation were collected in the isoform category ‘other’.
Dynamic model of splicing. We modelled the splicing dynamics using a set of
ordinary differential equations, in which concentrations of RNA intermediates are
determined by production and degradation terms (Supplementary Fig. 3a). The
pre-mRNA precursor x0 is produced at a constant rate c and spliced into ﬁve splice
products with linear kinetics and rates ri. All non-canonical isoforms are included
in the model as one additional species produced at rate r6. This leads to dx0/dt= c
−(r1+ r2+ r3+ r4+ r5+ r6)x0. Six additional differential equations describe the
dynamics of the canonical (AE inclusion, AE skipping, full IR, ﬁrst IR and second
IR) and non-canonical (other) splice isoforms. The concentration xi of isoform i is
described by dxi/dt=rix0–dixi, where di are RNA degradation rates.
The measured isoform frequencies correspond in the model to the
concentration of transcripts xi normalised by the total RNA concentration. These
fractions can be calculated analytically from the steady state of the system (see
Supplementary Note 1). As a result, we ﬁnd that the frequency pi of a certain
isoform i has the form pi= Ki/(K1+ K2+ K3+ K4+ K5+ K6). Here, the splicing
rates Kj= rj/dj, j= 1,2,4,5,6 are the ratios of production and degradation rates for
the isoforms involving splicing, and K3= 1+ r3/d3 reﬂects the sum of the unspliced
pre-mRNA (x0) and full intron retention (x3) isoforms, which cannot be
discriminated experimentally. Thus, due to normalisation, a change in the
production rate of one isoform due to a particular mutation will affect all isoform
frequencies, and this effect depends in a nonlinear manner on the values of all
splice rates Ki (i.e., on the mutational background). To infer the mutation effects
from the data, it is instructive to consider the isoform ratio relative to the inclusion
isoform (pi/p1= Ki/K1), as this no longer depends on all splice rates, and relates to
Ki in a linear fashion.
Calculation of single mutation effects by linear regression. For the estimation
of single mutation effects in HEK293T cells, we assumed that the combined log fold
changes of multiple mutations on a splice isoform ratio can be written as the sum
of individual log fold changes (see Supplementary Note 2). One such equation was
formulated for each minigene, resulting in a system of 5621–5697 equations for
each splice isoform ratio, depending on the amount of minigene variants that were
detected in the RNA-seq replicates (Supplementary Table 1).
To support our assumption of additive mutation effects, we analysed how single
mutation effects interact in minigenes containing several mutations. To this end,
we analysed a subset of mutations that is contained in the library as single mutation
minigenes (~600 minigene variants), and furthermore occur within double/triple
mutation minigenes together with other mutations from the list (Supplementary
Fig. 4a and Supplementary Table 1). For the majority of these mutations, we
observed that the combined mutational effects on the splicing rates Ki are
multiplicative, e.g., Ki(m1,m2)/Ki(WT)= Ki(m1)/Ki(WT)*Ki(m2)/Ki(WT), where
Ki(WT), Ki(m1), Ki(m2) and Ki(m1,m2) are the splicing rates of the wt minigene and
of the minigenes including mutation m1 or mutation m2 or both mutations m1 and
m2, respectively. In practice, we calculate the mutational effects Ki(m1,…mn)/
Ki(WT) as a mutation-induced fold change of the splice isoform ratios pi/p1 (see
above). By a log-transformation, the above multiplicative relationship transforms
to a linear one that connects the measured cumulative mutation effects with the
predominantly unknown single mutation effects (Supplementary Fig. 3a). For the
whole pool of measured minigene variants, this constitutes a system of linear
equations that can be solved for the single mutation effects in a least-square sense
(see Supplementary Note 2 for details).
As an alternative approach to estimate the single mutation effects, we calculated
the median isoform frequency across all minigene variants that harbour a given
mutation, and compared these numbers to the estimation of the regression model
(Supplementary Fig. 4b). If enough minigene variants with the mutation are
present in the library, this procedure should average out the effect of accompanying
mutations. The median isoform frequency for a mutation was independently
calculated for each isoform category and treated as a representative measure of the
splicing effect of this particular mutation.
Estimation of the inference accuracy of the model. The training data set con-
tained about ~600 mutations that were measured also as single mutations in
individual minigenes (Supplementary Table 1). We used these single mutation
minigenes to estimate the inference accuracy of the model, and to assess the
dependency of the inference accuracy on the occurrence of a mutation in the data
set. For each such mutation, the following cross-validation procedure was repeated:
The single mutation minigene was removed from the data set before ﬁtting the
regression model, and kept for the evaluation of the regression results. The
remaining minigenes containing the particular mutation were removed from the
data set successively and each time the effect of the mutation was assessed by
regression and the estimation compared to the single mutation minigene value. In
this way, we obtained estimates for the prediction error based on 1 up to n
−1 minigenes containing a particular mutation, where n is the total occurrence of
the mutation in the data set. In some cases, estimation of mutational effects was not
possible from a reduced data set, e.g., the prediction error for a particular mutation
was estimated only for occurrences between m and n−1, with 1 <m ≤ n−1. Finally,
the standard deviation of the inference errors for all mutations was estimated for
each measured frequency (Fig. 2c).
Signiﬁcant mutation effects and synergistic interactions. The estimated single
mutation effects on splice isoform ratios as obtained by linear regression could be
used to predict single mutation effects on each splice isoform frequency (pi) (see
Supplementary Note 2 for details). To quantify the effects of each individual
mutation on each isoform frequency, we calculated a z-score value from the model-
derived single mutation effects, using the mean and standard deviation of the 591
wt minigene variants:
pmutationi mean pwtið Þð Þ
Standard deviation pwtið Þ. The z-scores were independently calcu-
lated per replicate and later averaged. Only mutations present in all three replicates
were kept for further analyses.
In order to combine the evidence from the three replicate experiments, we
applied Stouffer’s test to combine the z-scores65. The resulting standard-normally
distributed metric was converted into a P value and subjected to multiple testing
correction (Benjamini–Hochberg). We considered a mutation as signiﬁcant for a
given isoform if it displays (i) ≥5% change in isoform frequency compared to the
mean of the 591 minigene variants (ΔIF ≥ 5%), and (ii) less than 5% false discovery
rate (FDR, adjusted P value <0.05). Combining all six isoform categories, this
approach identiﬁed 778 and 1022 splicing-effective mutations in HEK293T and
MCF7 cells, respectively (Supplementary Table 2). These accumulated into 469 and
550 splicing-effective positions, i.e., nucleotide positions in the RON minigene
where at least one out of three possible mutations shows a signiﬁcant effect on at
least one isoform.
To calculate z-scores for synergistic interactions between mutations and
HNRNPH knockdown from the model-derived isoform ratios, we divided the log-
transformed fold change in isoform ratios (KD over control condition) by the wt
variation (standard deviation; see Supplementary Note 3). z-scores were calculated
by replicates and then averaged, removing mutations that were not present in the
three replicates under KD conditions. We then used Stouffer’s test and multiple
testing correction as above. Since the uncertainty of the synergy z-score (measured
as the standard deviation between replicates) increases near 0% AE inclusion due to
boundary effects (Supplementary Fig. 7g), we excluded the splice sites
(positions 209–210, 298–299, 443–444, 523–524 and 689–690) mutations that on
their own completely abolish splicing (<1% isoform frequency under control
conditions). To identify signiﬁcant synergistic interactions, we applied a cutoff at
0.1% FDR (adjusted P value <0.001). Additionally, we required a consistent
directionality of the synergistic effects in all three replicates. Combining the ﬁve
different isoform ratios, this approach identiﬁed 354 signiﬁcant synergistic
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interactions (|z-score| > 2) on 278 positions between mutations and HNRNPH
knockdown in MCF7 cells (Supplementary Table 2). Applying more stringent
cutoffs at |z-score| > 3 or >5 identiﬁed 222 or 66 signiﬁcant synergistic interactions,
respectively (Supplementary Table 2).
Characterisation of splicing-effective positions. Splice site strengths were pre-
dicted using the sequence analysis software MaxEntScan29 for all mutations in the
positions considered by MaxEntScan (278–300 nt and 442–450 nt for the 3′ and 5′
splice site, respectively; Supplementary Fig. 9a, b). PhyloP scores66 were retrieved
from the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgTables; table:
Mammal Cons, PhyloP46wayPlacental) for the genomic coordinates corresponding
to the RON minigene (chr3:49933134–49933840, human genome version hg19;
Supplementary Fig. 9c).
Annotation of splice-regulatory RBP binding sites (SRBS). We used the Scan
Sequence tool of the ATtRACT database34 to identify potential RBP binding sites
along the RON wt minigene sequence. Duplicated records, e.g., due to overlapping
database entries from different experimental methodologies, were removed. We
retained only those binding sites for which ≥60% of positions were identiﬁed as
splicing effective in our screen. This step was independently performed for each
splice isoform. Within each RBP, these binding sites were then collapsed if they
shared an overlap of ≥2 nt and still harboured ≥60% splicing-effective positions for
at least one isoform after collapsing, if they did not fulﬁl this condition, they were
kept unmerged. For the comparison in Supplementary Fig. 12b, the HNRNPH
SRBS within each cluster were extended by 2 nt. Nucleotide positions in the two
isolated SRBS in the constitutive exons were excluded from this analysis.
In order to connect mutation effects to HNRNPH’s sequence speciﬁcity, G-run-
disrupting mutations were deﬁned as a G-to-H mutation at any position of the G-
run (used in Fig. 4c), while the two possible H-to-G mutations in immediately
neighbouring positions were counted as G-run-extending. Figure 4b compares the
median splicing effect (average of three biological replicates) of all G-run
disrupting versus extending mutations for the 22 predicted HNRNPH SRBS.
Analysis of TCGA and GTEx data. Normalised gene expression data for 11,688
post mortem samples from 30 human tissues, collected from 714 non-diseased
human donors, were retrieved from the GTEx project36 (v7). Normalised gene
expression data from TCGA tumour samples (https://cancergenome.nih.gov/) were
retrieved from Firebrowse (http://ﬁrebrowse.org/). Alternative splicing for both data
sets was quantiﬁed using psichomics (version 1.2.1, https://github.com/nuno-
agostinho/psichomics), using the default minimum coverage to calculate RON exon
11 PSI values. We quantiﬁed both gene expression and RON exon 11 PSIs for 2743
normal samples, from 24 healthy human tissues, and 4514 tumour samples, from 27
cancer types. The comparison of HNRNPH2 expression between tumours from
TCGA (9807 samples) and healthy tissues from GTEx (7851 samples) was done using
TPM values calculated at Toil67, which are already normalised for comparison.
Calculation of single mutation effects in cancer. Exome sequencing data from
TCGA tumour samples were downloaded from Genomic Data Commons Data Portal
(https://portal.gdc.cancer.gov/). We identiﬁed a total of 153 patients bearing 55 dif-
ferent mutations within the region of our RON minigene (Supplementary Data 5).
The impact on splicing of each mutation in the TCGA tumour samples was quan-
tiﬁed, per cohort, as the difference of RON exon 11 skipping (calculated as 1− PSI)
between mutated and non-mutated tumour samples. These differences were corre-
lated with those derived from the skipping isoform frequencies observed in our screen
for each mutation. Since we observed that the correlation was affected by the mini-
mum read coverage used to calculate PSIs, we restricted the correlation analysis to
cohorts with an average of more than 24 reads mapping to the involved splice
junctions (resulting in 117 patients from 14 cohorts harbouring 36 different muta-
tions; Fig. 3c). The intrinsic variability of RON exon 11 inclusion levels in TCGA
patient samples was calculated as the standard deviation of RON exon 11 PSI in
unmutated TCGA tumour samples (i.e., without a given mutation) from cohorts
considered in Fig. 3c and with more than 24 reads mapping to the involved splice
junctions.
Identiﬁcation of candidate RBPs. A recent large-scale RBP KD screen tested the
KD effect of >200 RBPs on splicing of RON exon 11 and other alternative exons in
HeLa cells35. The study used z-scores calculated from the PSI upon siRNA treat-
ment and the median absolute PSI deviation, divided by its standard deviation. A
positive z-score indicates more AE inclusion upon RBP KD. Using a cutoff of |z-
score| > 1.5, 125 RBPs showed a substantial effect on RON exon 11 splicing. These
include 17 RBPs that also have predicted SRBS in the RON minigene.
In order to identify potential regulators of RON exon 11 splicing in humans, we
searched for RBPs whose expression correlated with RON exon 11 splicing in
cancer. The correlation analysis was performed with 190 pre-selected RBPs,
consisting of 65 identiﬁed via ATtRACT, 108 identiﬁed in the previously published
RBP KD screen35 and 17 common to both approaches. The mRNA expression
levels of the RBPs were Spearman-correlated with RON exon 11 inclusion levels
across TCGA tumour samples (Supplementary Data 7 and Supplementary
Table 3). The signiﬁcance of those correlations (ranked by minus base-10
logarithm of the associated P value) was tested against those of all RBPs retrieved
from8 and of all protein-coding genes using Gene Set Enrichment Analysis (GSEA)
tool68,69. RBPs and protein-coding genes were ﬁrst restricted to the ones showing
at least the same average expression value as the least expressed pre-selected RBP,
known to be highly expressed in cancer, so that GSEA was not biased by gene
expression ranges. Moreover, we performed linear regressions between the
expression of each of the 190 pre-selected RBPs and RON exon 11 PSI in TCGA
tumour samples, using the resulting slopes to quantitatively assess the relative
magnitude of association between each RBP and RON exon 11 splicing.
Analysis of cooperativity and switch-like splicing behaviour. Changes in per-
cent spliced-in (ΔPSI) data for RON exon 11 inclusion from the endogenous RON
gene and the wt RON minigene measured at different HNRNPH knockdown (KD)
and overexpression (OE) levels (Supplementary Fig. 15a–d, 16) were ﬁtted using
the Hill function
y xð Þ ¼ ymax 
ymax  yminð ÞxnH
xnH þ EC50nH ;
with x and y being vectors of experimentally determined HNRNPH levels and
corresponding splicing outcomes (ΔPSI), respectively (Fig. 6b). ymin, ymax, EC50,
and nH are ﬁtted parameters. Fitting was done by minimising the residual cost
function
χ2¼ ΔPSI y HNRNPHð Þð Þ=σΔPSI;
where σΔPSI denotes the standard deviation of the PSI measurement. Minimisation
was done using the Matlab nonlinear least-squares solver lsqnonlin. The parameter
ranges used during ﬁtting were ymin∈ [−0.5,0], ymax∈ [0,0.5], EC50∈ [0.1,2] and
nH∈ [1,20]. The optimal parameter values found were
1. for the endogenous RON gene: ymin=−0.11, ymax= 0.36, EC50= 0.93, nH=
17.4
2. for the wt RON minigene: ymin=−0.11, ymax= 0.3, EC50= 0.94, nH= 13.8
Conﬁdence intervals were determined for all parameters by using a proﬁle
likelihood approach. For each ﬁtted parameter θ, the following workﬂow was
repeated: The parameter was assigned successively a number of values around its
optimal value θ0 listed above. While keeping this parameter at the ﬁxed value, the
remaining parameters were optimised and the value of the corresponding cost
function was determined. Thus, the dependence of the cost function χ2(θ) on the
parameter value around the minimum corresponding to the optimal value θ0 was
determined. The likelihood-based conﬁdence interval for this parameter is deﬁned
by
θ; χ2 θð Þ  χ2 θ0ð Þ<χ2 α; 1ð Þ
 
;
where α is the conﬁdence level and χ2(α,1) is the χ2 distribution with degree of
freedom 1. For each parameter, the 95% conﬁdence intervals were found by
determining the values θ on both sides of θ0, for which the likelihood χ2(θ) crosses
the threshold χ2(θ0)+ χ2(0.95,1).
The 95% conﬁdence intervals found for the endogenous RON gene were:
ymin 2 0:12;0:1½ ; ymax 2 0:28; 0:43½ ;
EC50 2 0:89; 0:95½ ; nH 2 10:8; 35:2½ ;
and for the wt RON minigene:
ymin 2 0:14;0:08½ ; ymax 2 0:3; 0:31½ ;
EC50 2 0:93; 0:95½ ; nH 2 10:4; 17:7½ ;
Code availability. Code that was used to generate the presented data is available
from the corresponding authors upon request.
Data availability. The sequencing data generated in this study are available from
ArrayExpress under the accession numbers E-MTAB-6216 and E-MTAB-6217
(RNA-seq), E-MTAB-6219 (DNA-seq), E-MTAB-6220 and E-MTAB-6221
(iCLIP). All other data supporting the ﬁndings of this study are available from the
corresponding authors on reasonable request.
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